Armata Pharmaceuticals, Inc. (NYSE: ARMP)

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections. The company operates in the biotechnology industry and is based in Marina del Rey, California.

Armata's main business activities revolve around the development of bacteriophage-based therapeutics. These are targeted therapies that aim to spare the human microbiome, reducing the risk of opportunistic infections. The company's proprietary technology enables the development of these targeted therapies, and it has several product candidates in its pipeline.

The company generates revenue through the development of its primary products, AP-PA02 and AP-SA02. AP-PA02 is being developed to treat chronic pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF) and non-CF bronchiectasis (NCFB). On the other hand, AP-SA02 is being developed to treat bacteremia due to acute infection with Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), as an alternative to antibiotics or to significantly limit the duration of antibiotic use.

Armata's position within the industry is strengthened by its competitive advantages. Its bacteriophage therapeutics have several advantages over traditional antibiotics. Phages are highly targeted to specific bacteria, sparing the human microbiome, and do not attack the normal human microbiome on the skin, the gut, or other areas critical to maintaining our defenses against more opportunistic infections. Phages also have a distinct mechanism of bactericidal action, which is independent of antibiotic resistance, and can be replicated competent, allowing for added functionality through genetic engineering.

Armata's customer base includes patients with antibiotic-resistant and difficult-to-treat bacterial infections. The company has received approvals from the U.S. Food and Drug Administration (FDA) to proceed with its Investigational New Drug (IND) applications for AP-PA02 and AP-SA02, and has initiated clinical trials for both products. Armata has also received funding from the Cystic Fibrosis Foundation and the Medical Technology Enterprise Consortium to support the development of its phage therapeutics.

Armata's product portfolio includes AP-PA02, AP-SA02, AP-PA03, and several other product candidates. AP-PA03 is being developed to treat other antibiotic-resistant and difficult-to-treat P. aeruginosa infections, such as acute bacterial pneumonia. AP-SA02 is also being developed for the treatment of other antibiotic-resistant and difficult-to-treat S. aureus infections, such as prosthetic joint infections and wound infections.